6 Reasons Your Antibody-Oligo Conjugates May be Underperforming
The use of antibody-oligonucleotide conjugates has grown rapidly in recent years, driven by advances in spatial biology, single-cell sequencing, multiplex imaging, immuno-PCR, and other highly sensitive molecular assays. The reliance of these applications on DNA-barcoded antibodies to enable highly multiplexed detection and quantitative analysis, is placing increasing demands on conjugation technologies.
Conventional NHS-based antibody-oligo conjugation kits have become a popular choice for researchers, offering a straightforward alternative to more technically demanding conjugation methods.
While this chemistry works well for attaching small molecules such as fluorophores, biotin and enzymes, conjugating oligonucleotides can present challenges. Oligos are highly charged, structurally complex molecules that vary in length and architecture. These characteristics can make them difficult to conjugate efficiently using conventional NHS-based approaches.
As molecular assays continue to evolve, many applications now require longer, more sophisticated oligos incorporating DNA barcodes, primer binding sites and other functional sequences. These increasing demands expose the limitations of conventional conjugation methods.
Here are six reasons why your antibody-oligo conjugate may be underperforming when using conventional NHS-based conjugation methods.
1. Random labeling creates heterogeneous conjugates
Conventional NHS conjugation approaches attach the oligo to the antibody via lysine residues that are naturally distributed across the antibody surface. Because these lysines are randomly present across each antibody, this can result in a different number of oligos attached at different locations.
The result is a heterogeneous mixture containing unconjugated antibodies, lightly labeled antibodies, and heavily labeled antibodies. This variability can affect assay performance and reduce reproducibility between batches.
2. Random attachment can affect antibody performance
Unlike small molecule labels such as fluorophores or biotin, oligonucleotides are relatively large, highly charged molecules. When they are attached at random locations on an antibody, there is no control over whether the oligo conjugation occurs close to antigen binding region or other functionally important sites.
If an oligo is attached near the antigen-binding site, its size may physically obstruct access to the target antigen or interfere with antigen recognition. In addition, the presence of a large, negatively charged DNA molecule can alter the local environment around the antibody, potentially affecting binding interactions or the way the antibody behaves in solution. Although binding is not always completely lost, even modest reductions in affinity or accessibility can have a significant impact on assay performance.
For applications such as spatial biology, immuno-PCR and multiplex imaging, where sensitive and reproducible target detection is essential, these effects can reduce signal quality, sensitivity and confidence in experimental results.
3. Longer and more complex oligonucleotides can present conjugation challenges
Many applications now require increasingly complex oligo constructs incorporating molecular barcodes, primer binding sites, amplification sequences and unique molecular identifiers.
Compared with shorter DNA tags, longer oligos are bulkier and more likely to fold into secondary structures, such as hairpins, which can reduce the accessibility of the reactive group during conjugation. Their increased size can also make efficient coupling more challenging.
As oligo length and complexity increase, conventional NHS-based methods often struggle to maintain efficient, reproducible conjugation.
4. Controlling the oligo-to-antibody ratio (OAR) is difficult
Many downstream applications require a defined oligo-to-antibody ratio (OAR) to ensure consistent signal intensity and accurate quantification.
Because conventional conjugation is based on random lysine modification, controlling exactly how many oligos become attached to each antibody is challenging. The resulting variability can lead to inconsistent fluorescence intensity, variable barcode counts and reduced quantitative accuracy.
As multiplexed assays become increasingly sensitive, controlling conjugate composition is becoming more important than ever.
5. Multiple purification steps increase sample loss
Traditional NHS-based workflows often require several processing steps, including antibody purification, buffer exchange, oligo activation, removal of excess linker, oligonucleotide coupling and final purification to remove unreacted DNA.
While each step improves product purity, every manipulation also reduces sample recovery.
This cumulative sample loss can become a significant challenge when working with expensive antibodies, limited clinical samples or custom-synthesised oligonucleotides.
6. Conventional workflows consume valuable reagents
Custom oligos often represent one of the most expensive components of an experiment.
To compensate for relatively inefficient coupling, conventional conjugation protocols frequently rely on excess amounts of modified oligonucleotide and antibody to drive the reaction forward. Unreacted material is subsequently removed during purification, increasing reagent consumption and overall experimental cost.
For laboratories routinely generating DNA-barcoded antibodies, these inefficiencies can quickly become both time-consuming and expensive.
The Case for Site-Specific Antibody-Oligo Conjugation
As DNA-barcoded antibodies become increasingly important for spatial biology, multiplex imaging and other next-generation molecular assays, many researchers are recognizing that conventional conjugation chemistries were not designed to meet the demands of antibody-oligo labeling.
Site-specific conjugation technologies are therefore becoming an increasingly attractive alternative. By attaching oligos at defined locations on the antibody, these approaches can help preserve antigen binding, provide precise control over the oligo-to-antibody ratio, simplify workflows and produce more consistent conjugates for demanding downstream applications.
oYo-Link® Oligo Custom applies this site-specific approach to enable simple, rapid and covalent conjugation of antibodies to custom oligos of virtually any sequence, length or modification.
Conjugation requires just 2 steps, mix oYo-Link Oligo with the antibody and illuminate with non damaging light for 2 hours. There are no oligo and antibody activation steps, no desalting steps, and oYo-Link is compatible with all common buffers, so no antibody purification is required.
Furthermore, because conjugation occurs site-specifically at the Fc region, the antigen-binding site remains untouched, eliminating the risk of interference with antibody binding.
In addition, the proprietary linker is designed to minimize steric effects, enabling efficient conjugation of even long and structurally complex oligonucleotides.
oYo-Link Oligo Custom also allows conjugation of as little as 1ug of antibody per reaction without the requirement for excess oligo, saving researchers on the cost of expensive reagents.
Simply specify your required oligo sequence and modifications, and we’ll source the HPLC-purified oligo on your behalf before supplying your custom oYo-Link® Oligo reagent. The cost of the custom oligo is included in the list price. Conjugation to your antibody is then completed in just two simple steps – mix and illuminate – with approximately 30 seconds of hands-on time.
Discover more about oYo-Link Oligo here, or contact our support team to find out how oYo-Link Oligo Custom can support your project.